US2010297257A1PendingUtilityA1

Anticoagulant antagonist and hemophillia procoagulant

69
Assignee: NAT INST OF HEALTH NIH U S DEPT OF HEALTH AND HUMAN SERVICES DHHSPriority: Nov 9, 2007Filed: Nov 3, 2008Published: Nov 25, 2010
Est. expiryNov 9, 2027(~1.3 yrs left)· nominal 20-yr term from priority
Inventors:Stephanie A. SmithJames H. Morrissey
A61K 33/42C12Q 1/56G01N 33/86A61K 38/36A61P 7/04
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

Claims

exact text as granted — not AI-modified
1 . A method for treating a coagulation deficient patient, comprising administering an amount of polyP to the patient sufficient to reduce a PT Test value or a Dilute PT Test value of plasma of the patient. 
     
     
         2 . The method of  claim 1 , wherein the polyP is polyP n , and n is at least 25. 
     
     
         3 . The method of  claim 1 , wherein the polyP is polyP n , and n is 25-1000. 
     
     
         4 . The method of  claim 1 , wherein the polyP is polyP n , and n is 25-100. 
     
     
         5 .- 9 . (canceled) 
     
     
         10 . The method of  claim 1 , wherein the patient has hemophilia. 
     
     
         11 . The method of  claim 1 , wherein the patient had previously been administered an anticoagulant. 
     
     
         12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the polyP is administered by injection. 
     
     
         14 . The method of  claim 1 , wherein the polyP is administered intravenously. 
     
     
         15 .- 17 . (canceled) 
     
     
         18 . The method of  claim 1 , wherein the polyP is polyP n , and n is 25-100,
 the PT Test value or Dilute PT Test value of the plasma of the patient is reduced to less than 1.5 times greater than the PT Test value or Dilute PT Test value of pooled normal plasma, and   the polyP is administered intravenously.   
     
     
         19 . (canceled) 
     
     
         20 . A method of reducing the effects of anticoagulant therapy on a patient, comprising administering polyP to the patient. 
     
     
         21 . The method of  claim 20 , wherein the polyP is polyP n , and n is at least 25. 
     
     
         22 . The method of  claim 20 , wherein the polyP is polyP n , and n is 25-1000. 
     
     
         23 . The method of  claim 20 , wherein the polyP is polyP n , and n is 25-100. 
     
     
         24 - 28 . (canceled) 
     
     
         29 . The method of  claim 20 , wherein the patient previously been administered an anticoagulant. 
     
     
         30 . (canceled) 
     
     
         31 . The method of  claim 20 , wherein the polyP is administered by injection. 
     
     
         32 . The method of  claim 20 , wherein the polyP is administered intravenously. 
     
     
         33 .- 37 . (canceled) 
     
     
         38 . A method of treating hemophilia in a patient, comprising administering polyP to the patient. 
     
     
         39 . The method of  claim 38  wherein the polyP is polyP n , and n is at least 25. 
     
     
         40 . The method of  claim 38 , wherein the polyP is polyP n , and n is 25-1000. 
     
     
         41 . The method of  claim 38 , wherein the polyP is polyP n , and n is 25-100. 
     
     
         42 .- 56 . (canceled)

Join the waitlist — get patent alerts

Track US2010297257A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.